As an overview, biologic medications including TNF-α inhibitors, IL-17 inhibitors, IL-1 inhibitors, and IL-12/23 inhibitors as well as oral medications including JAK inhibitors and PDE4 inhibitors have been investigated for use in patients with moderate-to-severe HS. Here, TNF is linked to histiocytic sarcoma.